Biotechnology - Sci-Tech Bulletin

compact gene silencing alzheimer’s research

Scientists Develop Compact Gene-Silencing Technology for Alzheimer’s Research

Researchers developed an all-in-one AAV epigenome-editing platform using catalytically inactive SaCas9 fused to KRAB and the MeCP2 transcriptional repression domain. The optimized system efficiently repressed target genes in cultured cells and maintained silencing through multiple cell divisions. In mouse hippocampus, the platform reduced reporter expression by approximately 45–60%. When directed against the endogenous Apoe gene, the system reduced ApoE expression by approximately 71% and 53% with two different guide RNAs. Preliminary mouse safety monitoring revealed stable body weight and normal behaviours, providing a preclinical proof-of-concept for programmable gene repression with potential applications in neurodegenerative disease research.

Scientists Develop Compact Gene-Silencing Technology for Alzheimer’s Research Read More »

Blood-Based Biomarkers for Early Alzheimer’s Diagnosis

Blood-Based Biomarkers Could Enable Early Alzheimer’s Diagnosis

The blood-based biomarkers could substantially improve Alzheimer’s disease diagnosis, prognosis and clinical-trial research. Studies highlight plasma p-tau217 and p-tau181 as a strong marker for detecting Alzheimer’s pathology and predicting future cognitive decline. Aβ42/Aβ40 may also provide additional value, especially for preclinical disease, while NfL is more useful as a marker of broader neurodegeneration and GFAP may help monitor disease activity. Blood biomarkers could reduce reliance on PET and CSF testing and make clinical-trial recruitment more efficient.

Blood-Based Biomarkers Could Enable Early Alzheimer’s Diagnosis Read More »

Anti-BCMA CAR-T Therapy for Multiple Sclerosis

Anti-BCMA CAR-T Therapy Shows Promise for Progressive Multiple Sclerosis

Chimeric antigen receptor (CAR) T-cell are increasingly being engineered to target specific antigens expressed by B-cell subsets, demonstrating enhanced tissue penetration and prolonged B-cell depletion across various autoimmune diseases. In a study of anti-BCMA CAR-T therapy in five patients with multiple sclerosis, the treatment demonstrated a favourable early safety profile, with 80% of patients experiencing only grade 1 cytokine release syndrome, while severe cytopenia occurred within 40 days of treatment. Furthermore, Clinical evaluations displayed CAR-T cells in blood, bone marrow, and cerebrospinal fluid (CSF), accompanied by plasma-cell depletion across these compartments.

Anti-BCMA CAR-T Therapy Shows Promise for Progressive Multiple Sclerosis Read More »

CRISPR-Cas Technology in Cheese Industry

How CRISPR-Cas Technology Is Transforming the Cheese Industry?

CRISPR-Cas systems have become important tools for strengthening lactic acid bacteria used in cheese production. Evidence summarized from Streptococcus thermophilus demonstrates that CRISPR spacer acquisition can generate phage-resistant bacterial mutants without adversely affecting technological properties. Sequential phage exposure can broaden resistance, while CRISPR array analysis can support bacterial strain genotyping. The endogenous CRISPR systems can also be repurposed for genome editing in LAB. However, dairy phages can evolve CRISPR escape mutations and anti-CRISPR proteins, creating an ongoing evolutionary challenge. Future applications should therefore combine CRISPR-Cas with complementary defence systems and continuous monitoring of dairy phage populations.

How CRISPR-Cas Technology Is Transforming the Cheese Industry? Read More »

Using CRISPR as a tool to identify Alzheimer’s Genes and Epigenetic Changes

CRISPR-Cas gene editing technology now can move Alzheimer’s disease research from genetic association toward functional validation. Studies highlight that CRISPR can be used to correct PSEN2 and PSEN1 mutations, investigate APP processing, and model APOE4-associated cellular changes in human iPSC-derived brain cells. As, found, APOE4 is linked to impaired Aβ clearance in astrocytes and microglia and increased Aβ42 secretion in neurons. Findings identify CRISPRi, CRISPRa and targeted DNA methylation editing as promising tools for investigating Alzheimer’s-associated epigenetic variation. Thus, CRISPR offers practical opportunities for disease modelling, causal-variant validation, drug discovery and high-throughput functional genomics, while significant technical limitations remain.

Using CRISPR as a tool to identify Alzheimer’s Genes and Epigenetic Changes Read More »

CRISPR Gene Editing Reveals New Targets for Powerful CAR-NK Cancer Therapy

Five genome-wide CRISPR screens were used to identify genetic regulators of antitumor activity and resistance to tumor-microenvironment stress, in primary human NK cells. Screening 19,281 genes under repeated tumor exposure, TGF-β, acidity and hypoxia identified MED12, ARIH2 and CCNC as key targets. Their knockout enhanced NK-cell and CAR-NK-cell cytotoxicity against treatment-resistant cancers while ARIH2/CCNC dual knockout improved metabolic fitness, activation, cytokine responses and cytotoxic-cell expansion. In pancreatic cancer and myeloma mouse models, edited CAR-NK cells showed improved tumor infiltration, reduced tumor burden and prolonged survival, supporting the development of next-generation, gene-edited CAR-NK therapies.

CRISPR Gene Editing Reveals New Targets for Powerful CAR-NK Cancer Therapy Read More »

Personalized RNA Neoantigen Vaccine Stimulate Powerful T-Cell Responses in Pancreatic Cancer

Autogene Cevumeran, an individualized uridine mRNA–lipoplex nanoparticle vaccine, was developed to target pancreatic ductal adenocarcinoma (PDAC). In a phase I clinical study, the vaccine was found to be feasible, tolerable, and capable of generating strong antitumor immune responses in patients with surgically resected PDAC. Among vaccinated patients, 50% developed high-magnitude, neoantigen-specific T-cell responses, including functional CD8+ T cells that persisted for up to two years and re-expanded after a booster dose. Importantly, responders experienced longer recurrence-free survival, supporting further investigation of autogene cevumeran as a strategy to delay pancreatic cancer recurrence.

Personalized RNA Neoantigen Vaccine Stimulate Powerful T-Cell Responses in Pancreatic Cancer Read More »

A New Cell-Free Technology for Sustainable Vitamin B12 Manufacturing

A synthetic cell-free platform has been developed by scientists, containing 36 enzymes to produce adenosylcobalamin, an active form of vitamin B12. The complex biosynthetic pathway starts with 5-aminolevulinic acid (5-ALA), an inexpensive compound, followed by more than 30 biocatalytic reactions optimized through enzyme screening, reaction-condition control, and cofactor regeneration. The optimized system produced 417.42 μg/L of vitamin B12 from 5-aminolevulinic acid and 5.78 mg/L from hydrogenobyrinic acid. The study thus demonstrates the potential of modular cell-free systems for manufacturing complex natural compounds beyond conventional microbial fermentation.

A New Cell-Free Technology for Sustainable Vitamin B12 Manufacturing Read More »

New Ebola Screening Platform, EBOV MiniG Plus, Advances High-Throughput Antiviral Drug Discovery

The EBOV MiniG Plus system could improve antiviral drug screening against Ebola virus under biosafety level 2 conditions. The study found that nucleocapsid proteins from several human coronaviruses, particularly SARS-CoV-2, significantly enhanced green fluorescent protein expression in the conventional Ebola virus minigenome system. Molecular analyses revealed increased transcriptional activity, with higher mRNA and cRNA levels. This enhanced system could achieve a higher Z-factor, indicating improved suitability for high-throughput screening. Testing with Remdesivir demonstrated concentration-dependent antiviral activity while maintaining comparable EC50 values, supporting its practical application in antiviral compound screening.

New Ebola Screening Platform, EBOV MiniG Plus, Advances High-Throughput Antiviral Drug Discovery Read More »

Carcimun® Blood Test shows 95.4% accuracy in identifying cancer

Carcimun® is a blood-based multi-cancer early detection test that measures optical changes in plasma proteins. The test achieved 95.4% accuracy, 90.6% sensitivity, and 98.2% specificity in distinguishing cancer patients from healthy participants and individuals with inflammatory conditions. As a minimally invasive testing approach, Carcimun® offers a potentially sensitive and practical tool for early cancer detection and screening. The test may eventually help clinicians identify patients who require further investigation earlier and more efficiently, potentially enabling timely medical attention and intervention at earlier stages of cancer.

Carcimun® Blood Test shows 95.4% accuracy in identifying cancer Read More »